Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
about
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideRemodeling Components of the Tumor Microenvironment to Enhance Cancer TherapyOverview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial FluidGlioblastoma Stem-Like Cells: Characteristics, Microenvironment, and TherapyModel driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisPotential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply.In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Effects of calcitriol on random skin flap survival in ratsNext generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai.Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.Tumour hypoxia causes DNA hypermethylation by reducing TET activity.Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Addressing intra-tumoral heterogeneity and therapy resistance.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Vessel pruning or healing: endothelial metabolism as a novel target?Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Bioinspired Hydrogels to Engineer Cancer Microenvironments.Calcitriol promotes survival of experimental random pattern flap via activation of autophagy.Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.Rethinking cancer nanotheranostics.Engineering and physical sciences in oncology: challenges and opportunities.Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.Astrocyte elevated gene-1 is overexpressed in non-small-cell lung cancer and associated with increased tumour angiogenesis.A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer.[Clinical Research on Albumin-bound Paclitaxel-based Therapy in Advanced Lung Cancer].TET enzymes as oxygen-dependent tumor suppressors: exciting new avenues for cancer management.The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.[Application of Bevacizumab in Non-small Cell Lung Cancer].Monitoring of tumor vascular normalization: the key points from basic research to clinical application
P2860
Q26770678-F0A9E3D7-14AC-4146-89C9-4EF63F13C043Q26777144-B9C4F87C-2C83-4290-A3F5-ED92CC3D0F12Q26799981-771B285F-2D2C-480D-AB31-908C89B493EFQ28079663-E798E131-154B-4EE6-9CA8-A470BD2AC1C8Q33618582-16923E9E-D100-4D1A-ABC2-ED228BE91FCEQ33624680-08EC78CF-2DE3-4387-8176-D6B09A7C6651Q33819576-14B61FA9-8619-4418-90D8-AA7EF0E5FB82Q36258054-0E3572D3-86BB-4CE4-B5BD-1632A5AD4CA2Q36306066-D0D23B0C-AB49-42F2-893A-019EE51E9CB3Q36432630-1FADB8A5-F750-4005-AA2B-4FAC97F8CEA8Q37458763-0F8A2236-6CF1-4467-ADC9-93F0AED916D8Q37461422-3302FC02-5AFC-4DF8-A618-7B5DA5E95214Q37463942-2E5AC833-7D4D-4D32-B218-265685F491D5Q37539775-1D7658BC-4205-4633-AE70-8FB02625AA55Q37562355-D6DF50C7-EAB0-4509-88A2-FACD3394E7E7Q37690917-E5272AA9-E6AF-4CB3-9CD9-46D8B505E986Q38823179-54957BCC-B093-46DC-94DD-A05C760E74D1Q39004424-EE3B096A-4BD4-4724-8EEB-8BF378BECBDCQ39024164-FF3DCF0A-DC3D-4E18-A8F3-1C5B20853CB7Q39210287-B6DC1733-E175-4823-A268-15919CC38961Q39386471-EA4FF3A9-A4DF-4077-8F17-EF24E5FA2D29Q41549294-4B9E1EB8-F3CB-4445-867F-01981594B235Q42332154-584F8EC8-5977-48EA-8FB0-4A9DB13934AFQ42332276-E6189E6A-F8D6-40E1-88D6-3D52B931A963Q42640884-6B29BF3A-5E1D-4B60-A490-5542FB23110DQ47244877-0DC1892A-ACDD-4165-A845-BB5442E980ECQ47346043-A221075F-EA0D-40B1-BBB8-A6AA51FDAE16Q50096986-BE568DA6-461A-4984-BABA-03AABF293E30Q51597242-2DBDEC29-CEA0-4291-B0F9-A40EB4AC0E23Q52576035-AEFF7063-FFEC-4AC3-AF6F-72B96079D797Q53145703-E60DCC25-6F5F-40A9-8AE0-BDFCA2225320Q53762480-93283612-82AA-4B7A-9896-C1D277E85DABQ54978333-ACB33409-E25F-4B70-8E41-6544DE77C32DQ55190117-9D18D624-D04B-48AF-A58E-84EB138E3B58Q55556494-4FEA4BE7-1C19-4B6F-9D2C-8AE6FFB0D848Q57484416-5DE9AB21-71A6-4C54-9B98-3436724A684D
P2860
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Improved tumor vascularization ...... with survival in lung cancer.
@ast
Improved tumor vascularization ...... with survival in lung cancer.
@en
type
label
Improved tumor vascularization ...... with survival in lung cancer.
@ast
Improved tumor vascularization ...... with survival in lung cancer.
@en
prefLabel
Improved tumor vascularization ...... with survival in lung cancer.
@ast
Improved tumor vascularization ...... with survival in lung cancer.
@en
P2093
P2860
P356
P1476
Improved tumor vascularization ...... with survival in lung cancer.
@en
P2093
Alice T Shaw
Dan G Duda
Dushyant V Sahani
Jeffrey A Engelman
Jennifer S Temel
Joel W Neal
Lecia V Sequist
Marek Ancukiewicz
Panos Fidias
Rakesh K Jain
P2860
P304
P356
10.1073/PNAS.1424024112
P407
P577
2015-01-20T00:00:00Z